Global Cancer Biomarker Market Size was valued at USD 28.5 Bn in 2024 and is predicted to reach USD 44.5 Bn by 2034 at a 4.7% CAGR during the forecast period for 2025-2034.
The cancer biomarker market is witnessing rapid growth due to increasing cancer incidences and advancements in diagnostic technologies. Biomarkers like PSA, CA125, and BRCA1/2 are crucial for early detection, prognosis, and personalized treatment. Factors such as rising awareness, government initiatives, and investments in R&D are driving market expansion. Additionally, liquid biopsy techniques and next-generation sequencing are gaining prominence for non-invasive and accurate cancer diagnosis.
However, challenges like high costs, stringent regulatory frameworks, and limited specificity hinder market growth. Overall, the cancer biomarker market is poised for significant expansion, propelled by technological advancements and increasing demand for personalized medicine. The increasing incidence of cancer, followed by awareness for early diagnosis, growing investments in research and development of cancer biomarkers, and extensive use of these biomarkers for diagnosis, drug discovery, and development are the key factors for the growth of this market. The COVID-19 pandemic adversely impacted the cancer biomarker market, causing disruptions in supply chains, delayed diagnosis and treatment, and reduced healthcare access. However, the market showed resilience with increased focus on research for COVID-19-related biomarkers and a shift towards telemedicine and remote patient monitoring, driving digital biomarker adoption.
In the cancer biomarker market, segmentation is based on the type of biomarkers and type of cancers. Biomarkers type segmentation includes Human Epidermal Growth Factor Receptor 2 (HER2), Mesenchymal Epithelial Transition (MET), Epidermal Growth Factor Receptor (EGFR), Programmed Death-Ligand 1 (PD-L1), Neurotrophic Tyrosine Receptor Kinase (NTRK), Anaplastic Lymphoma Kinase (ALK) and Other Biomarkers. The types of cancers include breast cancer, prostate cancer, colorectum cancer, lung cancer, thyroid cancer, bladder cancer, melanoma, non-Hodgkin lymphoma, endometrial cancer, kidney cancer, and leukemia.
The HER2 segment in the cancer biomarker market is a key area of focus, particularly in breast cancer diagnostics and treatment. HER2 is overexpressed in around 20% of breast cancers, making it a critical biomarker for prognosis and targeted therapy. The development of HER2-targeted therapies like trastuzumab has significantly improved patient outcomes. Continuous research in HER2 detection methods and personalized treatment strategies further drives growth in this segment.
The breast cancer biomarker segment is pivotal in early detection, prognosis, and personalized treatment of breast cancer. Additionally, novel biomarkers such as circulating tumor DNA (ctDNA) and microRNAs are being explored for their potential to improve diagnostic accuracy and monitor treatment response.
The North America cancer biomarker market is expected to register the highest market share. It can be due to its pharmaceutical industry and technological advancements. Additionally, North America has witnessed a tremendous increase in the adoption of biomarker testing for oncological disorders. The presence of a skilled workforce, advanced infrastructure, and a favorable business environment further results in the region's growth in the cancer biomarker market. In addition, Asia Pacific is estimated to grow at a rapid rate in the global Cancer Biomarker Market due to growing concerns about rapid industrialization, government initiatives, and increasing funding in various industries.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 28.5 Bn |
| Revenue Forecast In 2034 | USD 44.5 Bn |
| Growth Rate CAGR | CAGR of 4.7% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type of Biomarkers, Type of Cancer |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
| Competitive Landscape | Agilent, ARUP Laboratories, BioReference, Foundation Medicine, OncoDNA, Q² Solutions, Thermo Fisher Scientific, YuceBio, Asper Biogene, Caris Life Sciences, CeGaT, Genekor Medical, Guardant Health, Labcorp, MedGenome, NeoGenomics Laboratories, Nonacus, Oxford Gene Technology, Personal Genome Diagnostics, PhenoPath, Positive Biosciences, Quest Diagnostics, and Tempus. |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Cancer Biomarker Market- By Type of Biomarkers
Cancer Biomarker Market- By Type of Cancer
Cancer Biomarker Market- By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.